MAPK8 and nonpapillary renal cell carcinoma: The results showed that sunitinib, nilotinib, JNK inhibitor VIII, dasatinib, bosutinib, and bortezomib had lower 50% inhibitory values in the high-risk group than in the low-risk group, indicating that these drugs may be effective for treating ccRCC (p < 0.001, Fig. 7).